Nitisinone capsules are exclusively available through Optime Care, a specialised pharmacy committed to assisting patients dealing with rare diseases in effectively managing their conditions
Eton launches Nitisinone capsules to treat hereditary tyrosinemia type 1. (Credit: Steve Buissinne from Pixabay)
Eton Pharmaceuticals has launched Nitisinone capsules for the treatment of hereditary tyrosinemia type 1 (HT-1), in conjunction with a diet restricting tyrosine and phenylalanine.
Hereditary tyrosinemia type 1 is an exceptionally rare condition, estimated to affect fewer than 500 patients in the US.
Eton is a pioneering pharmaceutical company dedicated to the development, acquisition, and commercialisation of products tailored to address the unmet needs of patients grappling with rare diseases.
At present, the company boasts four FDA-approved rare disease products: Alkindi Sprinkle, Carglumic Acid, Betaine Anhydrous, and Nitisinone.
Furthermore, Eton is actively advancing three additional product candidates in late-stage development: ET-400, ET-600, and the ZENEO hydrocortisone autoinjector.
Eton Pharmaceuticals CEO Sean Brynjelsen said: “Eton is committed to serving patients and families with the rarest of conditions. We are proud to make Nitisinone available to the hundreds of patients in the United States and offer full patient and provider support services.
“We believe that our existing commercial infrastructure and strong patient support services should help us capture a meaningful percentage of the estimated $50m annual Nitisinone market.”
Nitisinone capsules are exclusively available through Optime Care, a specialised pharmacy committed to assisting patients dealing with rare diseases in effectively managing their conditions.
Optime Care, in collaboration with Eton Pharmaceuticals, will oversee the implementation of the Eton Cares Program.
Under the Eton Cares Program, all commercially insured patients will benefit from $0 co-pays, along with comprehensive services such as prescription fulfilment, insurance benefits investigation, educational support, and financial assistance for eligible patients.